IP Library Granted Patent US 12668817
Granted Patent B1
US 12668817 · App. 19/265,031 · Granted Jun 30, 2026

Recombinant adeno-associated viral vectors for delivering a therapeutic gene to lungs

Inventors: Lindsey Plasschaert (Barcelona, ES); Marta Gabasa-Ferrandez (Barcelona, ES)
Assignee: Telomere Therapeutics S.L.
C12N15/86C12N9/1276C12Y207/07049A61K48/00C12N2750/14143C12N2830/007C12N2830/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12668817
App. No.
19/265,031
Granted
Jun 30, 2026
Kind
B1
Abstract

The present invention provides a recombinant adeno-associated virus (rAAV) particle of 6.2 serotype comprising a recombinant nucleic acid comprising a lung-specific SpB promoter and a therapeutic gene, wherein the lung-specific promoter comprises SEQ ID NO: 1, and wherein said promoter is operably linked to and regulates the expression of the therapeutic gene.

Claims (19)

1 . A recombinant adeno-associated virus (rAAV) particle comprising:

a) a recombinant nucleic acid comprising a lung-specific SpB promoter and a therapeutic gene, wherein the lung-specific SpB promoter comprises SEQ ID NO: 1, and wherein the lung-specific SpB promoter is operably linked to the therapeutic gene, and

b) an AAV capsid of 6.2 serotype.

2 . The rAAV particle of claim 1 , wherein the therapeutic gene encodes for human telomerase reverse transcriptase (TERT).

3 . The rAAV particle of claim 1 , wherein the therapeutic gene encodes a protein comprising SEQ ID NO: 2 or 3.

4 . The rAAV particle of claim 1 wherein the AAV capsid of 6.2 serotype comprises a VP1 protein comprising SEQ ID NO: 15.

5 . The rAAV particle of claim 1 , wherein the therapeutic gene comprises SEQ ID NO: 8, 9, 11, 12, or 13.

6 . The rAAV particle of claim 5 , wherein the therapeutic gene comprises SEQ ID NO: 11.

7 . The rAAV particle of claim 1 , wherein the recombinant nucleic acid of a) further comprises a Kozak sequence upstream of the therapeutic gene.

8 . The rAAV particle of claim 7 , wherein the Kozak sequence comprises SEQ ID NO: 4.

9 . The rAAV particle of claim 1 , wherein the recombinant nucleic acid of a) further comprises a polyadenylation (Poly-A) signal placed downstream of the therapeutic gene.

10 . The rAAV particle of claim 9 , wherein the Poly-A signal is a bovine growth hormone polyadenylation signal.

11 . The rAAV particle of claim 1 , wherein the recombinant nucleic acid of a) further comprises a 5′-end and 3′-end inverted terminal repeat (ITR) sequences from AAV serotype 2 (AAV2).

12 . The rAAV particle of claim 11 , wherein the 5′-end and 3′-end AAV2 ITR sequences comprise SEQ ID NO: 6 and 7, respectively.

13 . The rAAV particle of claim 1 , wherein the recombinant nucleic acid of a) comprises SEQ ID NO: 10.

14 . A method of treating or preventing a lung disease comprising administering the rAAV particle of claim 1 to a subject in need thereof.

15 . The method of claim 14 , wherein the recombinant nucleic acid of a) comprises SEQ ID NO: 10.

16 . The method of claim 14 , wherein the lung disease is pulmonary fibrosis.

17 . The method of claim 16 , wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis.